China Research and Intelligence
China Research and Intelligence Market Research Reports
| Title | published | price | |
|---|---|---|---|
Investigation Report on China's Iodixanol Market 2021-2025By China Research and Intelligence
Iodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma. It is used for cardiovascular angiography, cerebrovascular angiography, abdominal angiography, and so on. Iodixanol was developed by Nycomed, a Norwegi ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Lenalidomide Market 2021-2025By China Research and Intelligence
Lenalidomide is an oral immunomodulatory drug that is mainly used to treat blood cancers such as multiple myeloma, myelodysplastic syndrome, and lymphoma. Lenalidomide was first developed by Celgene. Celgene's Lenalidomide, REVLIMID was launched in C ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Meropenem Market 2021-2025By China Research and Intelligence
Meropenem is an antibiotic that is used to treat a variety of bacterial infections, including meningitis, pneumonia and so on. Meropenem is jointly developed by Sumitomo Dainippon Pharma and Imperial Chemical Industries (ICI). It was launched in the ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Nivolumab Market 2021-2025By China Research and Intelligence
Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma. Nivolum ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Oseltamivir Market 2021-2025By China Research and Intelligence
Oseltamivir is an antiviral drug used to treat or prevent influenza virus type A and B. Oseltamivir was invented by Gilead Sciences, and Roche purchased the rights to develop and market Oseltamivir under the trade name TAMIFLU. Oseltamivir was launch ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Osimertinib Market 2021-2025By China Research and Intelligence
Osimertinib is a small molecule targeted anti-tumor drug used to treat non-small cell lung cancer (NSCLC). The original drug, TAGRISSO was developed by AstraZeneca. Osimertinib was launched in China in 2017, and it has been approved for two indicatio ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Rituximab Market 2021-2025By China Research and Intelligence
Rituximab is a monoclonal antibody to target cells that have the CD20 marker on their surface. It is mainly used to treat diseases caused by excessive B lymphocytes, including lymphoma, chronic lymphocytic leukemia, transplantation rejection, and cer ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Tacrolimus Market 2021-2025By China Research and Intelligence
Tacrolimus is a macrolide antibiotic and is also a new immunosuppressant. It is available in a variety of dosage forms. The ointment is used for moderate to severe atopic dermatitis where traditional therapies are not suitable, while the capsule and ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Trastuzumab Market 2021-2025By China Research and Intelligence
Trastuzumab is a monoclonal antibody used to treat breast cancer and stomach cancer, and is especially used for the treatment of certain HER-2 positive cancers. The original drug, HERCEPTIN was developed by Roche's subsidiary corporation. In 2002, Tr ... |
23-Apr-2021 | $2600 | |
Investigation Report on Chinese Clopidogrel Market 2021-2025By China Research and Intelligence
Clopidogrel is a medication that inhibits platelet aggregation and is mainly used to prevent atherosclerotic thrombosis. The original drug, Plavix, is developed by Sanofi. It enters the Chinese market in 2001. In addition to Sanofi, the other main ma ... |
23-Apr-2021 | $2600 | |
Investigation Report on China's Ambroxol Market, 2021-2025By China Research and Intelligence
The incidence and case fatality rate of respiratory diseases in China are high in recent years. Following cardiovascular and cerebrovascular diseases and cancers, respiratory diseases rank third among the chronic diseases that cause deaths in China. ... |
09-Apr-2021 | $2600 | |
Investigation Report on China's Hydroxychloroquine Market, 2021-2025By China Research and Intelligence
Hydroxychloroquine is commonly used to prevent and treat malaria. The pharmacokinetics of hydroxychloroquine is similar to that of chloroquine. It can be rapidly absorbed in the gastrointestinal tract and excreted in the kidneys. Hydroxychloroquine i ... |
09-Apr-2021 | $2600 | |
Investigation Report on China's Recombinant Lispro Insulin Market, 2021-2025By China Research and Intelligence
According to CRI analysis, China's rapid economic development in the past 30 years has brought about changes in people's lifestyles, such as a reduction in exercise and a continuous increase in calorie intake, leading to a continuous increase in the ... |
09-Apr-2021 | $2600 | |
Investigation Report on Chinese Adalimumab Market, 2021-2025By China Research and Intelligence
In 2010, Adalimumab entered the Chinese market. Its original drug is produced by AbbVie Inc., under the brand name HUMIRA. The sales of HUMIRA is ranking at Top one among all pharmaceutical products since it is used for a huge amount of disease treat ... |
09-Apr-2021 | $2600 | |
Investigation Report on Chinese Apixaban Market 2021-2025By China Research and Intelligence
Anticoagulation therapy plays an important role in the prevention and treatment of thromboembolic diseases. The two most famous drugs are Rivaroxaban and Apixaban, mainly used to prevent and treat venous thrombosis, and prevent systemic embolism caus ... |
09-Apr-2021 | $2600 | |
Investigation Report on Chinese Bevacizumab Market 2021-2025By China Research and Intelligence
Bevacizumab is the world's first humanized monoclonal antibody for anti-tumor angiogenesis, which can be used to treat colon cancer and other solid tumors. AVASTIN, the original research drug (developed by Roche Pharma), was approved in China in 2010 ... |
09-Apr-2021 | $2600 | |
Investigation Report on Chinese Budesonide Market 2021-2025By China Research and Intelligence
Budesonide is an adrenal cortex hormone medicine. It is available in different forms, such as inhalant, nasal spray, and so on. The inhalation form is used to treat asthma and chronic obstructive pulmonary disease. The nasal spray form is used to tre ... |
09-Apr-2021 | $2600 | |
Investigation Report on Chinese Dezocine Market, 2021-2025By China Research and Intelligence
Dezocine is an opioid analgesic that relieves pain. Dezocine was launched in China in 2009 and has been widely used in general anesthesia induction, postoperative analgesia, and preemptive analgesia. In the Chinese pharmaceutical marke ... |
09-Apr-2021 | $2600 | |
Investigation Report on Chinese Pembrolizumab Market, 2021-2025By China Research and Intelligence
Pembrolizumab is a humanized PD-1 monoclonal antibody used for cancer immunotherapy. It currently has the most approved indications, as well as it is used in more tumors' treatments than other drugs are. China approved Pembrolizumab's first indicatio ... |
09-Apr-2021 | $2600 | |
Investigation Report on Chinese Sevoflurane Market, 2021-2025By China Research and Intelligence
Sevoflurane is an inhalation general anesthetic and also the main inhalation anesthetic at this stage. Inhaled Sevoflurane was originally developed by Abbott and entered the Chinese market in 1996. In the Chinese market, with the preva ... |
09-Apr-2021 | $2600 | |
- + 1 888 391 5441
- [email protected]
